Does Mounjaro Cause Hair Loss in Females?

Why hair shedding happens during weight loss (and what Mounjaro's role really is

Telogen effluvium is what happens when the body experiences a significant physiological stress) rapid weight loss ranks alongside illness, surgery and major hormonal changes as a trigger. Normally around 10–15% of scalp hairs sit in the resting (telogen) phase before falling; when the body is under stress, a larger proportion enter that phase simultaneously, and three to four months later you notice increased shedding in the shower or on the brush.

The mechanism matters because it means the medicine itself is not directly attacking hair follicles. What the body is responding to is the speed and scale of weight reduction. Tirzepatide is highly effective: in the SURMOUNT-1 trial, participants lost an average of around 20% of body weight over 72 weeks, which is a profound physiological change. That same effectiveness is what makes transient hair shedding a relevant consideration for some women.

The NHS patient information for tirzepatide does not list alopecia among common reactions, common being defined as affecting more than 1 in 100 people. It appears in post-marketing reports for GLP-1 medicines as an uncommon finding. For a fuller picture of how Mounjaro's side-effect profile breaks down, the NHS medicines page for tirzepatide is the most reliable starting point in plain English.

Which women are more likely to notice it, and when

Not every woman on tirzepatide will experience noticeable shedding. Several factors appear to raise the likelihood. Losing weight very quickly in the early months is the biggest driver: the faster the deficit, the stronger the telogen signal. Women who were already borderline for iron, ferritin, vitamin D or zinc before starting treatment may find those stores depleted further during calorie restriction, amplifying the response. Thyroid conditions (already more common in women) can contribute independently, and starting a new weight-loss medicine is a reasonable prompt to check thyroid function if it has not been tested recently.

Timing is fairly predictable. Most women who report shedding notice it roughly 10–16 weeks after the period of sharpest weight reduction, which often corresponds to the first few months of treatment. It can feel alarming in the moment. The shedding does not mean follicles are permanently damaged; with telogen effluvium, growth usually resumes as the body adapts to its new weight and nutrition stabilises.

Protein intake is the single most practical lever available. During significant calorie restriction, many people eat less protein than their body needs to maintain lean tissue including hair. Aiming for adequate daily protein (a target your prescriber or a dietitian can help you set individually) is the intervention most consistently mentioned in clinical practice. You can read more about how women specifically experience this and what tends to help.

How to approach the decision about whether to continue

The honest framing is this: if tirzepatide is producing meaningful health benefits (better blood pressure, improved glucose control, reduced joint pain, sustainable weight reduction) temporary hair shedding is unlikely to outweigh those gains for most women. The question becomes different if the shedding is heavy, has not begun to slow after four to six months, or comes alongside symptoms such as fatigue, cold intolerance or scalp changes that could point to an underlying cause requiring treatment in its own right.

This is a conversation worth having with a prescriber rather than a decision made alone. The broader picture of how Mounjaro affects women covers the full side-effect context. If you are weighing up whether treatment is right for you at all, our prescribers discuss suitability and side effects as part of every consultation, starting yours is free, with no obligation.

For practical steps specifically aimed at managing shedding during treatment, guidance on reducing hair loss on Mounjaro covers what the evidence supports and what falls into the category of unproven.

When to get medical help, and how to report

Most hair shedding linked to rapid weight loss does not need urgent medical attention. It does warrant a GP or prescriber conversation if: the loss is in patches rather than diffuse shedding across the scalp; it has not begun to ease after four to six months of stable weight; it is accompanied by scalp soreness, redness or scaling; or you notice other unexplained symptoms such as significant fatigue, unintentional mood changes or swelling anywhere.

These could point to a separate condition (alopecia areata, thyroid disease, anaemia or a nutritional deficiency) that sits alongside your weight-management treatment rather than being caused by it, and each has its own management path.

The MHRA's Yellow Card scheme is how patients and clinicians report suspected side effects from any licensed medicine in the UK, including tirzepatide. If you experience hair loss you believe is linked to treatment, reporting it contributes to the national safety picture even if the link is uncertain. You can also find general context on Mounjaro and hair loss across all patients, not only women, if that broader comparison is useful. Our clinical team's approach to monitoring is outlined on the clinical team page.